Drug Approval | May 19, 2026
Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug
Baxfendy works in a fundamentally different way from current therapies
Baxfendy works in a fundamentally different way from current therapies
Access to genomic testing, not therapy cost, is the biggest challenge
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
The initiative by Rheumatology Association of Gujarat is aimed at strengthening patient-centric autoimmune care
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration
At the institute's 42nd convocation ceremony, Union Minister described its eight-institution MoU initiative as a unique collaborative effort that brings together premier national institutions to create a synergistic research ecosystem
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Subscribe To Our Newsletter & Stay Updated
